Document Type : Original Article
Authors
1 Department of virology and computational biochemistry, Anvek Institute of Biomolecular Research, Visakhapatnam, India.
2 Department of computational pharmacology, Anvek Institute of Biomolecular Research, Visakhapatnam, India.
Abstract
Keywords
Influenza viruses are enveloped viruses belonging to the Orthomyxoviridae family with a negative-sense, single-stranded, segmented RNA genome [1]. Influenza viruses are classified into four genera: influenza A, B, C, and D viruses [2]. Characterized with eight viral genomic segments, Influenza A virus (IAV) is known to cause respiratory infection in a wide range of hosts, including humans. IAV is known to cause seasonal epidemics and occasional pandemics in the human population and is a cause of concern with respect to general human health and well-being [3].
Non-structural protein 1 (NS1) is a multifaceted protein with a molecular weight of approximately 26 kDa and a sequence length of 215 to 237 residues encoded by the eighth segment of the IAV genome [4]. Ns1 protein consists of two domains, namely N-terminal domain (RNA binding domain; residues 1-73) and C-terminal domain (effector domain; residues 85-207) connected by a linker region (residues 74-84), while the final portion of residues (208-230/237) represent a disordered tail region [4]. NS1 protein contains two nuclear localization signal (NLS) namely NLS1 (residues 34-38) and NLS2/nucleolar localization signal (NoLS) (residues 216-237) in addition to a nuclear export signal (NES; residues 134-161) [5, 6]. NS1 protein plays an important role in suppressing host immunity, shutting off the expression of host genes, apoptosis, viral replication, and determination of virulence [7].
Ivermectin, an antiparasitic drug widely used in veterinary medicine owing to its broad-spectrum, safety, and efficacy [8], has been shown to have antiviral action in a wide variety of viruses. Ivermectin is an inhibitor of importin α/β-mediated nuclear import [9] and was reported to inhibit the nuclear import of human immunodeficiency virus 1 (HIV-1) integrase [9], simian virus 40 large tumor antigen (SV40 TAg) [10], dengue virus non-structural protein 5 (DENV NS5) [9], and block nuclear location signal in parvovirus [11]. Furthermore, ivermectin was reported to impede infection of dengue virus 1-4 [12], west Nile virus [13], Venezuelan equine encephalitis virus [14], influenza virus [15], pseudorabies virus [16], and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [17].
Four potential binding sites of ivermectin were found previously on the matrix protein 1 binding domain of the nuclear export protein (NEP) through structural similarity between the IAV NEP C-terminal domain and the structures with ivermectin as heteroatoms in the protein data bank [18]. In this study, IAV NS1 protein was targeted for drug repurposing study. Ivermectin was tested for its ability to bind with IAV NS1 protein utilizing in silico molecular docking technique.
The protein structure of IAV NS1 was retrieved from the protein data bank with PDB identifier 6O01 (https://www.rcsb.org/structure/6O01) [19]. The obtained .pdb file consisted of one chain, namely chain A. Residues 4-199 of IAV NS1 makeup chain A. Ivermectin structure (.sdf file) was retrieved from PubChem (https://pubchem.ncbi.nlm.nih.gov/compound/6321424) with PubChem CID 6321424 [20] (Fig. 1).
The IAV NEP was docked with ivermectin using CB-Dock docking server (http://cao.labshare.cn/cb-dock/) [21]. CB-Dock is a protein-ligand docking server performing blind docking involving four steps. First, putative binding sites are detected on the protein structure. Then, top binding sites are selected. The selection is based on the size of the binding sites. After that, the docking center is calculated, and the docking box size is adjusted. Finally, docking is carried out using AutoDock Vina, and after completion of docking, binding sites are ranked according to docking score [21].
IAV NS1 protein sequences were downloaded from National Centre for Biotechnology Information (NCBI) influenza virus resource [22]. Full-length sequences of NS1 from all hosts and subtypes were chosen, while duplicate protein sequences were removed. MAFFT version 7 was used with default parameters to align the obtained NS1 protein sequences [23].
A total of five binding sites for ivermectin were identified on NS1 with varying Vina scores. By default, the first conformation with the highest score is treated as the best binding position, and the corresponding site is the optimal binding site for ivermectin [21]. Ivermectin was found to bind IAV NS1 with a high AutoDock Vina score of -7.3 kcal/mol [cavity size: 194Å, center: -14*73*-46 (x*y*z) and size: 29*29*29 (x*y*z)] (Fig. 2). The ivermectin binding site residues identified on NS1 protein are Trp16, Lys20, Leu33, Leu36, Arg37, Asp39, Gln40, Leu43, Arg44 and Ile54.
A total of 17549 unique IAV NS1 protein sequences were obtained. Multiple sequence alignment was carried out using MAFFT version 7 [23]. Amino acid variation analysis was carried out at positions corresponding to the predicted ivermectin binding site on NS1 (Table 1).
Among the residues lining the ivermectin binding site, Trp16, Lys20, Leu36, Arg37, Asp39, Gln40, and Leu43 residues were found to be conserved. Residues Leu33 and Ile54 were found to be intermediately conserved, while residue Arg44 was found to be highly variable across various IAV hosts. Therefore, from the predicted binding site residues, seven are conserved, two are intermediately conserved, and only one residue is highly variable. Universally, the predicted ivermectin binding site is lined by conserved residues. These conserved residues might have either functional or structural importance, which might render them resistant to change in the evolution of the NS1 protein. Therefore this binding site is predicted to be highly resistant to future mutations.
The predicted binding site of ivermectin spans the NLS1 region of NS1 was reported to interact with human importin α protein and translocate across the membrane to the nucleus [24]. Thus, targeting this site with ivermectin might interfere with the translocation of NS1 protein. Targeting the IAV NS1 with ivermectin would probably have a deleterious effect on the infectious life cycle of IAV. Moreover, the predicted ivermectin binding site is mutation resistant. This makes ivermectin a promising universal anti-IAV drug molecule.
This study revealed a novel ivermectin binding site in the area overlapping NLS1 of NS1 protein. The identified binding site is universally conserved and resistant to mutations that could arise in the future. Ivermectin was found to bind with IAV NS1 protein strongly. It is anticipated that blocking the NS1 – importin α protein interaction can have a considerable deleterious effect on IAV NS1 protein dimerization and its nuclear import. Thereby the function of NS1 protein in the infectious life cycle of IAV would be disrupted, affecting the survival of IAV in the infected cell.
Conflict of interest statement
The authors declared no conflict of interest.
Funding statement
The authors declared that no funding was received in relation to this manuscript.
Data availability statement
The authors declared that all related data are included in the article.